Common TitleAPV29005
Official Title A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of fosamprenavir (GW433908)/Ritonavir BID when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18 years old and of fosamprenavir (GW433908) BID Administered to PI-Naive Pediatric subjects 2 to <6 years old
Phase Phase II
ClinicalTrials.gov NCT00089583
Treatments
Fosamprenavir
Fosamprenavir
Tradename:LexivaOther Names:FPVClass:Protease Inhibitors (PI)Categories PediatricsTreatment-Experienced
Funding
IndustryViiV Healthcare
References
- Fortuny C, Duiculescu D, Cheng K, et al. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children. Pediatr Infect Dis J. 2014;33:50-6.